In patients 30-75 years of age with an LDL‐C level ≥ 100 mg/dL (≥ 2.6 mmol/L) on maximally tolerated statin and ezetimibe therapy, the addition of a PCSK9 inhibitor may be considered. The monoclonal antibodies, alirocumab and evolocumab, are PCSK9 inhibitors that are administered by subcutaneous injection every 2 or 4 weeks. These agents have been shown to produce reductions in LDL-C of 50%-60% in patients with heterozygous FH. Another PCSK9 inhibitor, inclisiran, is a long-acting small interfering RNA therapeutic agent that inhibits the synthesis of PCSK9. Subcutaneous doses of inclisiran 300 mg can reduce LDL-C by > 50% for at least 6 months in patients with FH.
Two months after the addition of ezetimibe therapy, the patient returns for a follow-up visit. His LDL-C levels are still above target, and a PCSK9 inhibitor (evoculumab) is added to his treatment regimen.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Romesh Khardori. Skill Checkup: A Man With History of Heterozygous Familial Hypercholesterolemia and Premature Coronary Heart Disease - Medscape - Mar 17, 2023.